Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a common diabetes drug reshape PCOS metabolism?

NCT ID NCT07759674

Disease control Sponsor: Jerash Private University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 12, 2026 · Last updated Aug 13, 2026 · Updated 1 time

Summary

This trial follows women with polycystic ovary syndrome (PCOS) who take metformin, a standard diabetes medication, for six months. Researchers track changes in insulin resistance, iron levels, erythropoietin, cholesterol, and blood counts at three and six months. The goal is to see whether routine metformin therapy improves these metabolic and blood-related markers in women with PCOS.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Metformin hydrochloride tablets, 500 mg taken twice daily for six months
What this could lead to
If successful, this could clarify how metformin improves metabolic and iron-related health in women with PCOS, potentially guiding better management of the condition.
What could go wrong
This is a small, single-center study with 25 participants, so results may not apply broadly. Metformin can cause gastrointestinal side effects, and the trial does not compare against a placebo.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

25 people

The number who actually took part.

Started

Jun 2023

Finished

Dec 2023

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Women aged 18-45 years. * Diagnosis of polycystic ovary syndrome (PCOS) according to the Rotterdam diagnostic criteria. * Eligible for routine metformin therapy as determined by the treating gynecologist. * Willing and able to provide written informed consent. * Willing to attend scheduled follow-up visits and complete all study assessments over the six-month study period. Exclusion Criteria: * Pregnancy or breastfeeding. * Diagnosis of type 1 diabetes mellitus or established type 2 diabetes requiring insulin therapy. * History of chronic kidney disease, chronic liver disease, hematological disorders, malignancy, or other severe systemic diseases. * Current use of medications known to affect glucose metabolism, iron metabolism, erythropoietin levels, or hematological parameters within the previous three months, other than routine metformin prescribed as part of the study. * Known hypersensitivity or contraindication to metformin. Inability or unwillingness to complete the scheduled follow-up assessments. * Participation in another interventional clinical trial during the study period.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Insulin resistance syndrome are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Insulin Resistance metabolic syndrome X polycystic ovary syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Insulin resistance syndrome Polycystic ovary syndrome (PCOS) women

Contacts and locations

Locations

  • Ministry of Health Primary Healthcare Centers

    Amman, 009627, Jordan

More trials for these conditions

Other studies related to the condition(s) this trial covers.